Clinical Trial Update: Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial [Phase 2]

View source ↗

Summary

The NERA trial, a Phase 2 study of erdafitinib with or without atezolizumab in localized bladder cancer patients ineligible for cisplatin chemotherapy, has been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer
• Upper Tract Urothelial Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Erdafitinib (erdafitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Bladder Carcinoma, Bladder Urothelial Carcinoma | Phase 2 | Status: WITHDRAWN